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Overexpression of the Human endogenous retrovirus W (HERV-W) group of inherited
retroviruses has been consistently linked with Multiple Sclerosis (MS). However most of
the studies on this link have focused on European genetic groups with a very high risk of
MS and it is not clear that this relationship holds for all ethnic groups. This study examined
via qPCR the RNA expression in peripheral blood of HERV-W (the multiple sclerosis
associated retrovirus variant MSRV) of MS patients and healthy controls from two ethnic
groups with very different risk rates of MS. Population one was derived from the UK with a
Northern European genetic background and an MS risk rate of 108/100,000, population
two was derived from the republic of Tatarstan, Russian Federation, with a mixed Russian
(Eastern European) and Tartar (Turkic or Volga/Urals) population with an MS risk rate of
21-31/100,000. The Russian population displayed a significantly higher basal level of
expression of MSRV in both healthy and MS individuals when compared to the British
control population with a trend in the Russian population towards higher expression levels
in MS patients than healthy patients.
Keywords: human endogenous retrovirus W, multiple sclerosis, multiple sclerosis associated retrovirus, human
endogenous retrovirus, ethnicityINTRODUCTION
Multiple sclerosis (MS) is a chronic, progressive autoimmune neurological disease. The disease is
often debilitating with few effective treatment options currently available. The underlying triggers
for the disease are complex and be best summed up as: MS occurring in genetically susceptible
individuals who are exposed to the “right” environmental triggers. A familial association is evident
in some cases and some distinct restricted genetic groups (such as Sardinians) (Pugliatti et al., 2001)
have a high risk. Extensive GWAS studies have demonstrated a compelling support for the
HLA allele DRB1*15:01 as the most significant genetic risk factor for MS, with smaller effectsin.org January 2020 | Volume 10 | Article 16451
Tarlinton et al. HERV-W in Two Different Ethnic Groupsattributed to another 11 HLA alleles and 200 non HLA genes
(Didonna and Oksenberg, 2017). Other risk factors for MS
include gender (women are at higher risk than men), prior
Epstein Barr Virus infection, Vitamin D levels (those with
lower levels at higher risk).
The prevalence of MS also shows distinct regional variations
with the highest rate in Northern European and North American
populations. Also, prevalence increases with latitude in countries
and this is thought to be linked to UVB exposure and subsequent
vitamin D levels. With notable exceptions for certain populations
such as the Sardinians and artic peoples with diets very high in
fish oils (and vitamin D). Relapses of clinical disease are also
associated with season (with a peak in spring) and low vitamin D
levels (Harding et al., 2017). Immunoregulatory effects of
vitamin D are believed to play role in MS pathogenesis. This
assumption is based on data demonstrating distinct seasonal
patterns in cytokine profile (and therefore basal inflammatory
states) in a variety of disorders including MS (Blatt et al., 2017;
Goodin, 2016; Watad et al., 2016).
Endogenous retroviruses (ERVs) are vestiges of retroviral
infections from evolutionary history that remain in the host
genomes. They make up to 8% of the human genome and are
present in all vertebrates (Hayward et al., 2013). While not
replicating as infectious viruses in humans they can be
expressed in some individuals and are linked to the disease
pathogenesis. There is a strong epidemiological link between the
expression of the HERV-W retroviral family and Multiple
Sclerosis (Morandi et al., 2017a). HERV-W is an attractive
candidate for the link between the genetic and environmental
factors in MS for a number of reasons. The envelope protein or
mRNA of certain HERV-W loci are expressed constitutively in
normal human tissues, particularly in the placenta (the syncytin
locus), with certain HERV-W RNA sequences isolated from MS
patient samples known as multiple sclerosis associated retrovirus
(MSRV) (Nellaker et al., 2009; Bhat et al., 2011; Soygur and
Moore, 2016). Interestingly HERV-W is upregulated in the brain
of MS patients (Morandi et al., 2017a) when compared with
healthy controls. Upregulation of HERV-W can be reliably
induced by Epstein Barr and other viral infections (Nellaker
et al., 2006; Mameli et al., 2012). The HERV-W Env protein also
induces a pro-inflammatory responses and neuronal pathology
similar to that found in MS (Perron et al., 2013; Morandi et al.,
2017b). Intriguingly HIV patients receiving antiretroviral
medication are seemingly protected from MS and there have
been clinical trials of antiretroviral drugs targeted at HERV-W as
MS therapeutics (Morandi et al., 2017b).
Despite this epidemiological data few studies have looked at
whether there are differences in HERV-W expression between
populations with high and low MS prevalence, or populations of
distinctly different genetics, despite this being highlighted as a
potential confounding factor in the use of HERV-W expression
as a marker of MS disease (Morandi et al., 2017a). This
study reports HERV-W expression in MS patients and healthy
controls in two distinct populations with very different ethnic
makeups and MS risk. The two study locations, the East
Midlands in the UK and the Republic of Tatarstan in RussiaFrontiers in Pharmacology | www.frontiersin.org 2are at approximately the same latitude but have a different
climate, the main differences being in the temperatures of the
coldest months (below 0 Celsius in Tatarstan) (Peel et al., 2007).
The prevalence of MS is very different between the two sites with
a rate of 97-108/100,000 in the UK site (Kingwell et al., 2013)
and 21-31/100,000 for the Tatarstan site (Simpson et al.,
2011). The ethnic mix of the populations also very different
with the East Midlands 85% White British (Northern
European), with a sizeable (7%) South Asian minority (Office
for National Statistics, 2011) and Tatarstan, 40% Russians
(Eastern Europeans), 53% Tatars and large minorities of other
groups such as the Chuvashes (3%) (Volga, Ural/Turkic)
(Federal State Statistics Service, 2010). Within the Tatarstan
population there is a documented lower incidence of MS in the
Tatar population when compared with the Russian (Bakhtiiarova
and Magzhanov, 2006). Within the East Midlands population
there is also a lower incidence of MS in the South Asian
compared with the White British population (Albor et al., 2017).MATERIALS AND METHODS
Human Blood Samples
Blood samples from patients attending Nottingham University
Hospitals NHS Trust or the Republican Clinical Neurological
Center, Republic of Tatarstan, Russian Federation were collected
in PAXgene Blood RNA tubes (Qiagen). The Russian samples
were shipped to Nottingham as PAXgene tubes. MS diagnosis
was established according to the McDonald criteria (Polman
et al., 2011). All patients and health controls (HC) signed
informed consent for which ethical approval was obtained. In
total 43 UK patients (21 HC and 22 MS) and 25 Russian patients
(7 HC and 18 MS) gave samples. Patients and HC age, gender,
and clinical status are presented in Supplementary Table 1.
Ethnicity data where available is presented.
Ethics statement: Informed consent was obtained from each
subject according to the clinical and experimental research
protocol, approved by the Nottingham Research Ethics
Committee 2 (Ref 08/H0408/167) and the Biomedicine Ethic
Expert Committee of Republican Clinical Neurological Center,
Republic of Tatarstan, Russian Federation (N: 218, 11.15.2012).
RNA Extraction and cDNA Synthesis
RNA processing for all samples was performed in Nottingham.
Total RNA was purified using the PAXgene Blood RNA kit
(Qiagen) following the manufacturer’s instructions. The RNA
was treated with DNase to remove trace amounts of bound DNA.
After the wash steps, RNA was extracted in the elution buffer
provided with the kit and stored at -80°C. RNA concentration
was determined by measuring the absorbance at 260 nm using
NanoDrop ND-100 (Thermo Scientific). For making cDNA, 0.5
mg RNA samples, 2 ml Random hexamers and 1 ml dNTPs mix
(stock solution 10 mM) (all Promega) were mixed, followed by a
5 min incubation at 65°C for first strand cDNA synthesis. A
master mix containing RNase inhibitor (Promega, UK), DTTJanuary 2020 | Volume 10 | Article 1645
Tarlinton et al. HERV-W in Two Different Ethnic Groups(0.1M) and 5X First-Strand Buffer was added, along with
Superscript III RT (220 U/ml) (all from Invitrogen, UK).
Negative controls replacing the RNA template or the RT with
DNase/RNase free H2O were included. Samples were incubated
as followed: 5 min at 95°C, 60 min at 50°C and 25 min at 70°C.
cDNA was stored at -80°C.
qPCR
Relative quantification was performed using Ubiquitin C (UBC)
and Ubiquitin conjugating enzyme E2D2 (UBE2D2) as
housekeeping genes as per published literature on stable
reference genes for use in PBMC in Multiple Sclerosis (Oturai
et al., 2016). For detection of HERV-W nine hundred nM of
probe/forward and reverse primer mix “MSRV” (Mameli et al.,
2009) forward primer CTTCCAGAATTGAAGCTGTAAAGC,
reverse primer GGGTTGTGCAGTTGAGATTTCC, Probe
FAM-5′-TTCTTCAAATGGAGCCCCAGATGCAG-3′-TAMRA
(Invitrogen custom Taqman assay) UBC and UBE2D2 (TaqMan
gene expression assays, Invitrogen, catalogue numbers
Hs05002522_g1 and Hs00366152_m1 both FAM-MGB probes)
were used. All samples were run in duplicates. Agarose
gel electrophoresis of the MSRV primers used in endpoint
PCR produced amplicons of the expected size (166 bp)
(Supplementary Figure 1) QPCR was performed using a
BioRad CFX Connect (BioRad) and Faststart Universal probe
master (Roche) in 96-well plates with the following cycling
conditions: 10 min at 95°C and 40 cycles of 10 s at 95°C
followed by 30 s at 60°C. A control sample not subjected to
reverse transcription (a “no RT control”) was included in each
batch of samples and did not amplify in any instance. Primer
efficiencies were calculated from the slope of a standard curve and
were 87.2% for HERV-W, 96.8% for UBC and 93.8% for UBE202.
Calculation of the relative amounts of HERV-W was performed
using the two reference genes with one HC used as a calibrator.
Any change in gene expression between patient cohorts and the
calibrator HC patient was expressed using the following formula
Relative gene expression =
(EGOI)
DCTGOI
GeoMean½(Eref )DCTref 
Where GOI = HERV-W, ref = UBC, UBE2D2, E =
amplification factor (10[–1/slope]), DCT = Calibrator CT-
Sample CT.STATISTICAL ANALYSIS
Statistical analysis was performed using Graph Pad Prism 5,
Kruskal Wallis test with Dunn’s multiple comparison test post
hoc testing. Data are presented as medians and interquartile ranges.RESULTS
There was a significant difference in HERV-W relative
expression between the populations (Russian HC, Russian MS,Frontiers in Pharmacology | www.frontiersin.org 3UKHC, and UKMS) (P < 0.0001 Kruskal Wallis) (Figure 1). On
post-hoc testing (Dunn’s multiple comparison test), there were
significant differences (P < 0.05) between the UK and Russian
populations but not between the MS and HC within the two
populations, though there is a clear trend in the Russian group
towards a higher HERV-W expression in the MS patients
(Figure 1). The Russian patients were divided into those
sampled at first presentation (who had not yet had disease
modifying therapy) and those seen at follow up visits. There
was a significant difference in these cohorts when compared
to the Russian healthy controls (P = 0.0095 Kruskal Wallis)
(Figure 2). On post-hoc testing (Dunn’s multiple comparison
test), there were significant differences between the Russian
patients on primary presentation and Russian healthy controls
but not the other two groups Though a trend, albeit with quite a
bit of variability, towards highest HERV-W expression levels in
those on primary presentation, an intermediate level of HERV-
W expression in those on follow up visits and the lowest levels in
healthy controls can be seen (Figure 2).
CONCLUSIONS
This study quite clearly shows differences in the expression levels of
HERV-W between the UK and Russian populations that are
statistically significant. While not statistically significant there is a
clear trend in the Russian cohort (but not the UK cohort) towards a
higher expression of HERV-W in MS patients than the healthy
controls. Other factors such as gender did not display clear
differences. The differences between the MS and healthy patients
are in line with the reported increase in detection of HERV-W inFIGURE 1 | Relative expression of HERV-W against the reference genes
UBC and UBE2D2, calibrated against a healthy control (UK) sample. Medians
and interquartile ranges are indicated by bars. HC, healthy control, MS,
multiple sclerosis, UK, United Kingdom, RUS, Russian (N = 21 UK HC, 22 UK
MS, 7 RUS HC, 18 RUS MS), (Medians = 0.98 UK HC, 0.58 UK MS, 11.51
RUS HC, 17.40 RUS MS), Kruskal Wallis P < 0.001, Dunn’s Multiple
comparison test P < 0.05 for differences between the Russian and UK
cohorts but not between MS and HC. HERV-W, Human endogenous
retrovirus W; UBC, Ubiquitin C; UBE2D2, Ubiquitin conjugating enzyme E2D2.January 2020 | Volume 10 | Article 1645
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and meta-analysis in (Morandi et al., 2017a). One caveat is that this
study examined HERV-W RNA from whole blood in PaxGene
tubes whereas previous studies in the (Morandi et al., 2017a) meta-
analysis used a variety of blood derivatives including PBMC, and
plasma so the results are not directly comparable. However to our
knowledge no previous studies have examined ethnic or population
differences in HERV-W expression.
There are a number of potential explanations or confounding
factors that could potentially explain these differences. The
choice of an unstable housekeeping gene is a common cause of
false conclusions from this type of qPCR study, however we
performed stability experiments with 5 patients from each cohort
(UK MS, UK HC, RUS MS, RUS HC) using a selection of genes
from the published work on selection of stable reference genes in
PBMC in MS and healthy patients (Oturai et al., 2016) with
concordant results to the published work and are confident that
this difference is not a technical error. The primer/probe
combinations used here not span exon junctions so genomic
DNA contamination is a possibility, though at no stage did any
of the controls not subjected to reverse transcriptase amplify,
indicating that DNA contamination was not present. Even if
there were DNA contamination in these samples we do not really
expect the copy number of the reference genes or HERV-W loci
to vary substantially between individuals so the use ofFrontiers in Pharmacology | www.frontiersin.org 4normalisation against the reference genes still should take this
into account as a potential confounder. The two populations live
at approximately the same latitude removing that as a source of
variation in MS risk factors, largely leaving background genetics/
ethnicity as the potential explanation of this large difference.
It is also possible that the handling conditions during
transport of the Russian samples to the UK, or RNA
extractions performed at different time points could have
resulted in systematic bias in the HERV-W RNA stability.
These loci do not produce virions (which might protect viral
RNA while cellular RNA is degraded) and it is hard to image
what other processes would have selectively affected the HERV
transcripts and not the reference genes. The use of multiple
reference genes in relative qPCR studies such as this is
specifically designed to balance variations in sample quality
and as far as is possible with this study design is the best
method currently available to account for this potential
confounding factor.
Sample size is also another potential confounding factor and
as always these findings will require verification by other groups
and with other cohorts of patients. Increasing the sample size is
unlikely to change the statistical significance of the differences
between the two populations as these are really quite large (there
is indeed no overlap in the confidence intervals) and power
calculations based on the results in this study give quite trivial
numbers (single digits) for confirming the differences between
the populations. The differences in the MS patients versus the
healthy controls in each population are more subtle and in the
case of the British population would require several thousand
participants to confirm with confidence, a clearly very different
scale of study to the current one.
This study was not designed to stratify differences between
stage of disease and HERV-W expression with all the British
patients being in the remission phase of the disease and the
Russian patients at varying stages with too few patients in each
group to adequately compare stage of disease and HERV
expression therefore the differences between the Russian patients
at first presentation and at later stages of disease need to be taken
with some caution. It is possible that stage of disease has also
contributed to the differences between the UK and Russian
populations, as there is some indication in the Russian cohort
that those at first presentation and not currently being treated with
disease modifying therapies had higher HERV-W expression,
though without longitudinal studies comparing the same patient
through relapse and remission this is hard to quantify.
There are several potential explanations for this difference
in HERV-W expression; the first is that there may be
polymorphisms in the number (presence or absence) or
sequence of the HERV-W loci between the two populations.
This may affect either the expression profile of the loci or their
ability to be detected with the qPCR used in this study. Such
polymorphism has recently been reported for HERV-W
(Thomas et al., 2018). With the advent of long range deep
sequencing technologies capable of distinguishing repetitive
loci such as HERVs it may now be possible to determine if
such polymorphisms exist between the UK and RussianFIGURE 2 | Relative expression of HERV-W against the reference genes
UBC and UBE2D2, calibrated against a healthy control (UK) sample. Medians
and interquartile ranges are indicated by bars. RUS MS1 = Russian patients
on primary presentation (before any disease modifying therapy) RUS MS2 =
Russian patients on follow up visits (on a variety of disease modifying
therapies) (N = 25, RUS MS1 = 7, RUS MS2 = 11 and RUS HC = 7)
(Medians = 17.63 RUS MS1, 16.67 RUS MS2 and 11.51 RUS HC) Kruskal
Wallis P = 0.0047, Dunn’s Multiple comparison test P < 0.05 for differences
between the RUS MS1 and RUS HC cohorts only. HERV-W, Human
endogenous retrovirus W; UBC, Ubiquitin C; UBE2D2, Ubiquitin conjugating
enzyme E2D2; HC, healthy control; MS, multiple sclerosis; UK, United
Kingdom; RUS, Russian.January 2020 | Volume 10 | Article 1645
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presented here. Furthermore, epigenetic dysregulation or cell
specific promotor activation of genes other than HERV-W loci
(but that may interact with HERV-W expression) are other
factors that require exploration in the population differences in
HERV expression in the current study.
It is possible that expression of particular defective alleles may
even be protective against the expression of deleterious alleles (or
exogenous virus) as has been described in other species such as
JSRV in sheep (Armezzani et al., 2014). Another possibility is
variation in cellular factors that normally suppress HERV
expression such as the Trim 5a and APOBEC 3G systems
(Fadel and Poeschla, 2011).
Why the expression of a known risk factor for MS is higher in
a population with a lower risk of the disease is puzzling, though it
seems likely that other genetic or epigenetic factors must be in
play here. There has been some work indicating that epitopes of
the HERV-W envelope protein could be recognised by the HLA
alleles DRB1*1501 and DRB5*0101 (Ramasamy et al., 2017).
Therefore, it could be suggested that the failure of HLA allele
recognition of the higher levels of HERV-W expression in the
RUS MS cohort may account for some of the difference in MS
risk. It is however clear that there are population differences in
MSRV expression and that this needs to be taken into account
when comparing patient cohorts for this risk factor for MS.ETHICS STATEMENT
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